CELL INTELLIGENCE · 肿瘤细胞治疗研究

可扩展生成靶向实体瘤的造血干细胞工程化现成单特异性细胞毒性 T 细胞

Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors.

肿瘤细胞治疗的进展与前景：从 T 细胞到干细胞的探索

Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.

分泌 IFNα/抗 PD-L1 的工程化 TCR-T 细胞增强内源性免疫以协同提升抗实体瘤疗效

Engineered TCR-T cells secreting IFNα/anti-PD-L1 potentiate endogenous immunity to synergistically bolster the efficacy against solid tumors.

用于癌症过继性细胞治疗的细胞类型定制水凝胶

Cell-Type-Tailored Hydrogels for Adoptive Cell Therapy in Cancer.

用于癌症免疫治疗的异体 T 细胞平台的工程化策略

Engineering Strategies for Allogeneic T Cell-Based Platforms in Cancer Immunotherapy.

T 细胞限制性 IL15 和 IL21 协同装甲 CAR 与 TCR T 细胞普遍增强实体瘤疗效

Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.

膜锚定 IL15 与 IL21 的共表达是一项增强工程化 T 细胞抗实体瘤韧性与功能的技术，可能适用于多种治疗平台和疾病。

实体瘤细胞免疫治疗进展

Progress in cell-based immunotherapies for solid tumors.

实体瘤细胞免疫治疗：进展、挑战与未来方向

Cell-based immunotherapies for solid tumors: advances, challenges, and future directions.

恶性肿瘤过继性细胞免疫治疗的现状与前景

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.

急性髓系白血病使治疗性 WT1 特异性 CD8 TCR-T 细胞偏向 NK 样表型，损害其功能与持久性

Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.